Puregon50 IU

Puregon is a recombinant human follicle-stimulating hormone (FSH) used in the management of infertility. Its approved and evidence-supported uses include:

• Ovulation induction: In anovulatory infertile women whose infertility is functional (not due to primary ovarian failure), to stimulate follicular development and induce ovulation.
• Controlled ovarian stimulation (COS): In normally ovulatory women undergoing assisted reproductive technology (ART) procedures such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), used together with a subsequent human chorionic gonadotropin (hCG) trigger injection.
• Spermatogenesis induction in men: In men with primary or secondary hypogonadotropic hypogonadism, used in combination with hCG to stimulate sperm production.

Puregon is always used under the close supervision of a fertility specialist with appropriate monitoring facilities (ultrasound and hormone assays); it is not intended for self-directed use without such monitoring.

Follitropin Beta is a recombinant human FSH, a dimeric glycoprotein produced by recombinant DNA technology in a mammalian (Chinese hamster ovary) cell line. Its amino acid sequence and biological activity are indistinguishable from naturally occurring pituitary/urinary human FSH. It is available as a sterile injectable solution or as a lyophilized powder with accompanying solvent for reconstitution, in various international unit (IU) strengths, for subcutaneous or intramuscular administration.

Puregon belongs to the gonadotropin class of hormonal medicines. It works by mimicking the action of the body's own follicle-stimulating hormone, stimulating the growth and maturation of ovarian follicles in women and supporting sperm production in men. It is used only under specialist supervision as part of a structured fertility treatment cycle, typically combined with hCG and close ultrasound/hormonal monitoring to reduce the risk of over-response.

Puregon belongs to the therapeutic class of Gonadotropins, specifically recombinant follicle-stimulating hormone (r-hFSH) preparations used in fertility treatment and assisted reproduction.

Follitropin Beta acts by binding to FSH receptors located on the surface of ovarian granulosa cells (in women) and testicular Sertoli cells (in men).

• In women: It stimulates the growth, development, and maturation of ovarian follicles and promotes the production of gonadal steroid hormones (mainly estradiol) by the growing follicles. Final oocyte maturation and follicular rupture require a subsequent hCG injection.
• In men: When given together with hCG (which maintains intratesticular testosterone), Follitropin Beta stimulates Sertoli cell function and supports spermatogenesis.

Pharmacokinetically, Follitropin Beta has comparable bioavailability by the subcutaneous and intramuscular routes, an elimination half-life of roughly 24-40 hours, and reaches steady-state serum levels after about 3-5 days of daily dosing.

Puregon is given by subcutaneous injection (occasionally intramuscular), usually self-administered by the patient or a caregiver after proper training, using a pre-filled pen, cartridge, or reconstituted vial/ampoule as supplied. Injection sites (abdomen or thigh) should be rotated to reduce local irritation. If a powder formulation is dispensed, it must be reconstituted with the accompanying solvent immediately before use (see Reconstitution) and not mixed with other medicinal products in the same injection unless specifically directed by the treating physician. Injections are usually given at approximately the same time each day for consistent hormone levels.

No formal drug-drug interaction studies have been conducted with Puregon. It is routinely and intentionally co-administered with human chorionic gonadotropin (hCG) as part of standard fertility protocols, and is sometimes used together with a GnRH agonist or antagonist to prevent premature LH surge/ovulation during controlled ovarian stimulation; these combinations are expected and managed by the treating specialist. Concomitant use of other hormonal medications (e.g., clomiphene citrate) should only occur under specialist guidance, as they may alter ovarian response and the required dose of Puregon.

The most common side effects reported with Puregon include:

• Headache
• Pelvic or lower abdominal pain/discomfort
• Ovarian cysts
• Nausea
• Injection site reactions (redness, pain, bruising)
• Fatigue
• In men: acne, injection site pain, gynecomastia

A more serious but less common risk is ovarian hyperstimulation syndrome (OHSS) — see Precautions and Warnings for full detail. Uncommon effects include hypersensitivity reactions (including anaphylaxis) and thromboembolic events.

Puregon is contraindicated once pregnancy is confirmed and has no indication for use during an established pregnancy. It is used only to achieve pregnancy, under specialist supervision, and treatment is stopped once ovulation/pregnancy occurs (aside from the trigger hCG dose). There is no evidence that gonadotropin use itself increases the rate of congenital malformations beyond the general population background risk, but multiple-pregnancy and IVF-related factors can independently increase risk; this should be discussed with the treating physician. It is not known whether Puregon passes into human breast milk; a physician should be consulted before use in a breastfeeding woman, weighing the benefits of breastfeeding against the clinical need for treatment.

Puregon should only be used under the supervision of a physician experienced in fertility treatment, with access to ultrasound and hormonal monitoring. Key warnings include:

• Ovarian Hyperstimulation Syndrome (OHSS): A potentially life-threatening condition involving rapid ovarian enlargement, fluid shifts, and third-spacing (ascites, pleural effusion). Early warning signs include severe pelvic pain, nausea, vomiting, and rapid weight gain; if these occur, treatment should be stopped and the physician contacted immediately. Risk is reduced by using the lowest effective dose and careful monitoring, and by withholding the hCG trigger if the ovarian response is excessive.
• Multiple pregnancy: Gonadotropin therapy including Puregon increases the risk of twin or higher-order multiple pregnancy, which carries greater maternal and perinatal risk; patients should be counseled before starting treatment.
• Ovarian torsion: A rare but serious complication associated with OHSS and enlarged ovaries; presents with sudden severe abdominal pain and requires urgent evaluation.
• Thromboembolism: Rare cases of venous or arterial thromboembolic events (including deep vein thrombosis, pulmonary embolism, stroke) have been reported, particularly in women with additional risk factors such as obesity or a personal/family history of thrombosis.
• Ectopic pregnancy: Women with a history of tubal disease are at increased risk of ectopic pregnancy following fertility treatment; early ultrasound confirmation of an intrauterine pregnancy is recommended.

Regular monitoring (ultrasound and estradiol levels in women; testosterone and semen analysis in men) is required throughout treatment with Puregon.

Specific data on acute overdosage of Puregon are limited. Excessive dosing is expected to increase the risk of ovarian hyperstimulation syndrome and multiple pregnancy in women. If overdose is suspected, discontinue the medicine and seek immediate medical attention or contact emergency services; the treating fertility specialist should be informed promptly so that appropriate monitoring and supportive care can be arranged. No specific antidote exists.

Store Puregon refrigerated at 2°C to 8°C, protected from light, and do not freeze, unless the product labeling for the specific brand permits limited room-temperature storage (check the pack insert). Once a multi-dose cartridge/pen is in use, follow the manufacturer's in-use storage period and discard after the stated number of days. Keep out of reach of children, and do not use after the expiry date printed on the pack.

Pediatric use: Puregon is not indicated for use in children; safety and efficacy in pediatric patients have not been established.

Geriatric use: Not applicable, as this medicine is used within the reproductive age range for its approved indications; clinical studies in patients 65 years and older have not been conducted.

Renal/hepatic impairment: Specific dose-adjustment data in significant renal or hepatic impairment are not well established; use with caution and specialist judgment in such patients.

Body weight: Clearance per kilogram is broadly consistent across different body weights, but total drug exposure can vary with body weight; the treating physician may adjust dosing accordingly.

For ovulation induction and controlled ovarian stimulation, a single treatment cycle with Puregon typically lasts about 7 to 14 days, ending with the hCG trigger injection; the number of cycles attempted is decided by the fertility specialist. For spermatogenesis induction in men, treatment is generally continued for a minimum of 3-4 months, as a visible response in sperm production may take up to 12 months; hCG pretreatment for several months often precedes the addition of Puregon in men.

Where Puregon is supplied as a lyophilized (freeze-dried) powder in a vial or cartridge with a separate solvent ampoule/syringe, it must be reconstituted immediately before use: inject the provided solvent gently into the powder vial without shaking vigorously, and swirl gently until the powder is fully dissolved into a clear, colorless solution. Do not use if the reconstituted solution is cloudy or contains particles. Reconstituted solution should generally be used immediately unless the product labeling states otherwise, and any unused portion of a single-use vial should be discarded. Pre-filled pen/cartridge presentations of Puregon do not require reconstitution.

Follitropin Beta belongs to the drug class of Gonadotropins (Recombinant Follicle-Stimulating Hormones), used in the treatment of infertility.

Follitropin Beta binds to and activates the FSH receptor on ovarian granulosa cells in women, stimulating follicular growth, development, and estradiol production, and on testicular Sertoli cells in men, supporting spermatogenesis when combined with hCG. It reproduces the physiological action of endogenous pituitary FSH.

X

Puregon has no approved use in pediatric patients. It is indicated only for adults undergoing fertility treatment (women undergoing ovulation induction or assisted reproduction, and adult men with hypogonadotropic hypogonadism). Safety and efficacy in children and adolescents have not been established.